WO2003008451A3 - Modification of human variable domains - Google Patents

Modification of human variable domains Download PDF

Info

Publication number
WO2003008451A3
WO2003008451A3 PCT/EP2002/008094 EP0208094W WO03008451A3 WO 2003008451 A3 WO2003008451 A3 WO 2003008451A3 EP 0208094 W EP0208094 W EP 0208094W WO 03008451 A3 WO03008451 A3 WO 03008451A3
Authority
WO
WIPO (PCT)
Prior art keywords
modification
variable domains
human variable
constructs
optimization
Prior art date
Application number
PCT/EP2002/008094
Other languages
French (fr)
Other versions
WO2003008451A2 (en
Inventor
Stefan Ewert
Thomas Huber
Annemarie Honegger
Andreas Plueckthun
Original Assignee
Univ Zuerich
Stefan Ewert
Thomas Huber
Annemarie Honegger
Andreas Plueckthun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich, Stefan Ewert, Thomas Huber, Annemarie Honegger, Andreas Plueckthun filed Critical Univ Zuerich
Priority to JP2003514009A priority Critical patent/JP4355571B2/en
Priority to EP02772101A priority patent/EP1406931A2/en
Priority to CA002453662A priority patent/CA2453662A1/en
Priority to US10/484,105 priority patent/US20060127893A1/en
Publication of WO2003008451A2 publication Critical patent/WO2003008451A2/en
Publication of WO2003008451A3 publication Critical patent/WO2003008451A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to a method for the optimization of isolated human immunoglobulin variable heavy (VH) and light (VL) constructs.
PCT/EP2002/008094 2001-07-19 2002-07-19 Modification of human variable domains WO2003008451A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003514009A JP4355571B2 (en) 2001-07-19 2002-07-19 Modification of human variable domains
EP02772101A EP1406931A2 (en) 2001-07-19 2002-07-19 Modification of human variable domains
CA002453662A CA2453662A1 (en) 2001-07-19 2002-07-19 Modification of human variable domains
US10/484,105 US20060127893A1 (en) 2001-07-19 2002-07-19 Modification of human variable domains

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01116756 2001-07-19
EP01116756.6 2001-07-19

Publications (2)

Publication Number Publication Date
WO2003008451A2 WO2003008451A2 (en) 2003-01-30
WO2003008451A3 true WO2003008451A3 (en) 2004-01-29

Family

ID=8177996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008094 WO2003008451A2 (en) 2001-07-19 2002-07-19 Modification of human variable domains

Country Status (5)

Country Link
US (1) US20060127893A1 (en)
EP (1) EP1406931A2 (en)
JP (1) JP4355571B2 (en)
CA (1) CA2453662A1 (en)
WO (1) WO2003008451A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102838673B (en) * 2007-06-25 2016-05-11 艾斯巴技术-诺华有限责任公司 The method of modified antibodies and there is the modified antibodies of functional character of improvement
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation
USRE49435E1 (en) 2014-11-12 2023-02-28 Seagen Inc. Glycan-interacting compounds and methods of use

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160440A1 (en) * 2003-12-12 2011-06-30 Genencor International, Inc. Cab Molecules
EP2395026B1 (en) 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Method for improving antibody
BRPI0711229A2 (en) 2006-05-31 2013-01-08 Astellas Pharma Inc humanized anti-human osteopontin antibody, polynucleotide, expression vector, host cell, method for producing a humanized anti-human osteopontin antibody, therapeutic drug, method for preventing or treating autoimmune disease, and use of humanized west anti-human antibody
CA2677804C (en) 2007-02-12 2017-03-14 Proteonova, Inc. Generation of library of soluble random polypeptides linked to mrna
EP2118138A1 (en) 2007-03-12 2009-11-18 Esbatech AG Sequence based engineering and optimization of single chain antibodies
WO2009000098A2 (en) * 2007-06-25 2008-12-31 Esbatech Ag Sequence based engineering and optimization of single chain antibodies
CA2777242A1 (en) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
MX2014002289A (en) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Tandem fc bispecific antibodies.
AU2014225661A1 (en) 2013-03-06 2015-09-10 Merrimack Pharmaceuticals, Inc. Anti-c-Met tandem Fc bispecific antibodies
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
IL258768B2 (en) 2015-11-12 2023-11-01 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use
CA3029332A1 (en) 2016-07-01 2018-01-04 Ludwig Institute For Cancer Research Ltd Methods and compositions for pdgf-cc inhibition
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. Glycan-interacting compounds and methods of use
KR20240044544A (en) 2017-03-03 2024-04-04 씨젠 인크. Glycan-interacting compounds and methods of use
CN112292394A (en) * 2018-06-08 2021-01-29 文塔纳医疗系统公司 Generic or normalized antibody framework for improved functionality and manufacturability

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006213A1 (en) * 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993017105A1 (en) * 1992-02-19 1993-09-02 Scotgen Limited Altered antibodies, products and processes relating thereto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006213A1 (en) * 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993017105A1 (en) * 1992-02-19 1993-09-02 Scotgen Limited Altered antibodies, products and processes relating thereto

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JUNG SABINE ET AL: "Selection for improved protein stability by phage display.", JOURNAL OF MOLECULAR BIOLOGY, vol. 294, no. 1, 19 November 1999 (1999-11-19), pages 163 - 180, XP002249461, ISSN: 0022-2836 *
NIEBA LARS ET AL: "Disrupting the hydrophobic patches at the antibody variable/constant domain interface: Improved in vivo folding and physical characterization of an engineered scFv fragment.", PROTEIN ENGINEERING, vol. 10, no. 4, 1997, pages 435 - 444, XP002249462, ISSN: 0269-2139 *
WILLUDA JORG ET AL: "High thermal stability is essential for tumor targeting of antibody fragments: Engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment.", CANCER RESEARCH, vol. 59, no. 22, 15 November 1999 (1999-11-15), pages 5758 - 5767, XP002249463, ISSN: 0008-5472 *
WORN ARNE ET AL: "Stability engineering of antibody single-chain Fv fragments.", JOURNAL OF MOLECULAR BIOLOGY, vol. 305, no. 5, 2001, pages 989 - 1010, XP002249286, ISSN: 0022-2836 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102838673B (en) * 2007-06-25 2016-05-11 艾斯巴技术-诺华有限责任公司 The method of modified antibodies and there is the modified antibodies of functional character of improvement
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9573995B2 (en) 2013-05-06 2017-02-21 Scholar Rock, Inc. Compositions and methods for growth factor modulation
USRE49435E1 (en) 2014-11-12 2023-02-28 Seagen Inc. Glycan-interacting compounds and methods of use

Also Published As

Publication number Publication date
JP2005504526A (en) 2005-02-17
CA2453662A1 (en) 2003-01-30
EP1406931A2 (en) 2004-04-14
WO2003008451A2 (en) 2003-01-30
JP4355571B2 (en) 2009-11-04
US20060127893A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
WO2003008451A3 (en) Modification of human variable domains
AU2002359851A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
WO2003087131A3 (en) Anti-her2 antibody variants
WO2003030833A3 (en) Angiopoietin-2 specific binding agents
WO2002030986A3 (en) HUMANIZED ANTI-LT-β-R ANTIBODIES
AU2001294175A1 (en) Method of purifying antibody
AU2002255353A1 (en) Photosensitive coloring compositon, color filter using the compositon and method of producing the same
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
AU2001251184A1 (en) Method of raising capital for early stage companies through broker-dealer
AU2002326531A1 (en) Monoclonal antibodies to activated erbb family members and methods of use thereof
AU2002317367A1 (en) Predistorting of contention signals
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
WO2003016501A3 (en) Recombinant antibodies, and compositions and methods for making and using the same
AU6028501A (en) Trivalent antibody constructs having variable regions that are stabilized by disulfide bridges
AU2003255150A1 (en) Method of producing tortional damper
AUPQ026799A0 (en) Method of increasing protein stability by removing immunoglobulin aggregates
AU2001261628A1 (en) Cd28 synthebody for the modulation of immune responses
WO2003059259A3 (en) Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
AU2002359566A1 (en) Method of transforming intact plants
AU2002347562A1 (en) Method of enabling e-commerce
AU2002360394A1 (en) Facilitation of rna interference
AU2002365272A1 (en) Epsilon immunoglobulin chain derived peptides for induction of anti-ige antibodies
AU2003303381A1 (en) Methods for treating malaria by modulation of g protein function
WO2003031584A3 (en) Axon repair
AU2002323460A1 (en) Tubular igniter bridge

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2453662

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003514009

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002772101

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002772101

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2006127893

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10484105

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10484105

Country of ref document: US